The new recombinant vaccine against tuberculosis reached Phase II of the trials, which will involve 300 people, saidArtem Tkachuk, the Head of Translational Biomedicine Laboratory at N.F. Gamaleya Federal Research Center of Epidemiology and Microbiology.
“We are developing new vaccines and one of them is a recombinant vaccine. It is intended to extend the immunological memory in adults who had received BCG vaccine in their childhood according to the immunization schedule… At the end of 2017, we completed a fairly large study for Phase I of the trials involving 60 people,” said Mr. Tkachuk by adding that no adverse events were reported in the study.
The funds have been already allocated to continue this work over the next two years. The program is financed from the state budget and provides for the allocation of about 60 million rubles in 2018 and about 30 million in 2019.
“In 2019, we expect to complete a fairly large study, which will include several medical centers in Russia… Currently, there is the interest expressed by our colleagues from South East Asia, in particular, from Malaysia… For the national phase, we plan to involve 300 people and may be more, and if we manage to reach the international level, then we plan to involve additional 600 thousand people,” said Mr. Tkachuk.